5-Isopropyl-3-methylbenzonitrile | 1349717-12-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Isopropyl-3-methylbenzonitrile
• 英文别名: 3-methyl-5-propan-2-ylbenzonitrile
• CAS: 1349717-12-9
• 化学式: C₁₁H₁₃N
• 分子量: 159.23
• InChiKey: UYVZNFRIHLCKCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Novel HIV reverse transcriptase inhibitors
  申请人：Guo Hongyan

  公开号：US20080070920A1

  公开（公告）日：2008-03-20

  The invention is related to compounds of Formula (I), (II), or (III): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  这项发明涉及到以下化合物的公式(I)、(II)或(III)： 或其药用可接受的盐、溶剂化合物、酯和/或膦酸酯，含有这种化合物的组合物，以及包括给予这种化合物的治疗方法。
• KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
  申请人：AMGEN INC.

  公开号：US20180177767A1

  公开（公告）日：2018-06-28

  Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供了KRAS G12C抑制剂，其组成，以及使用方法。这些抑制剂对治疗多种疾病有用，包括胰腺癌、结直肠癌和肺癌。
• NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US20210047287A1

  公开（公告）日：2021-02-18

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

  本文介绍了一些能够调节生长抑素的化合物，制备这些化合物的方法，包含这些化合物的药物组合物和药品，以及使用这些化合物治疗需要调节生长抑素活性的疾病、病症或疾患的方法。
• NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS
  申请人：Guo Hongyan

  公开号：US20100034827A1

  公开（公告）日：2010-02-11

  The invention is related to compounds of Formula (I), (II), or (III); or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  本发明涉及公式(I)、(II)或(III)的化合物；或其药学上可接受的盐、溶剂化合物、酯和/或膦酸酯，含有这些化合物的组合物以及包括给予这些化合物的治疗方法。
• Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof
  申请人：Hardy Larry Wendell

  公开号：US20110319380A1

  公开（公告）日：2011-12-29

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。本文中提供的化合物可用于治疗、预防和/或管理各种疾病，如神经系统疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5(mGluR5)的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。